Both the Finnish and the U.S. bird flu vaccines are made by CSL Seqirus but are different vaccines. In the summer, U.S. officials stockpiled 4.8 million doses of the vaccine that officials said was ...
In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal ...
To that end, HHS has granted Moderna $590 million to help accelerate the development of a bird flu vaccine. The agency announced its backing of the Massachusetts-based pharmaceutical firm about 72 ...
Previous bird flu outbreaks and decades-old public health infrastructure have led industry to protect the hens used for ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...
The FDA has accepted Moderna's BLA and has assigned a PDUFA goal date of June 12, 2025. Seasonal flu + COVID vaccine: Moderna shared positive Phase 3 immunogenicity data for its flu/COVID ...
During the fourth quarter, Moderna submitted three mRNA products for regulatory approval, including its "next-generation" Covid shot, combination shot targeting Covid and the flu and RSV vaccine ...